Rodríguez LO, Pichardo GR, Escamilla GG, Hernández-Valencia M

Language: Spanish
References: 16
Page: 12-17
PDF size: 124.82 Kb.

ABSTRACT

The cells of cervix are very active in the reproductive life, for which the constant activity promotes the abnormal growth of the cells when conjugate risk factors for development of cervical pathology. This has been established as cause of cervical dysplasia, that have evolution to cervico-uterine cancer (CuCa) when associates to the human papilloma-virus. The cervical neoplasias constitute 21.4% of total malignes and 85% of gynecological neoplasias. The prevention of CuCa can be carried out through the opportune detection, oriented to avoid or to diminish risk factors, for which to utilize condom, delay the initiate of sexual life and to limit the number of couples are measures that should know the general population. It should have present that number of gestation and age of initiate the sexual life are associated risk factors to the factors already established for cervical wound.

REFERENCES

1. U.S. National Institutes of Health. Cáncer del cuello uterino: Tratamiento. National Cancer Institute; 2005.

2. Secretaría de Salud. Programa Nacional de Prevención y control del Cáncer Cérvico uterino en México. México: SSA; 1997.

3. Educación Médica Continua. Cáncer cervical. On Line. México.

4. SSA. Norma Oficial Mexicana para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino; 1997.

5. Chute DJ, Covell J, Pambuccian SE, Stelow EB. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests. Diagn Cytopathol 2006; 34: 503-6.

6. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm 2007; 24: 4-8.

7. Salud Reproductiva e investigación. Prevención del cáncer cervical en las comunidades de escasos recursos. Organización Mundial de la Salud 2000; 18(1).

8. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006; 12: 6167-71.

9. Inoue M, Sakaguchi J, Sasagawa T, Tango M. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006; 16: 1007-13.

10. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States 2003-2005. Ann Intern Med 2008; 148: 132-6.

11. Hernández QT, Illanes AB, Salas LN, Alarcón RLC, Hernández-Valencia M. Evaluación del tratamiento con imiquimod en infección persistente por el virus del papiloma humano con el método de reacción en cadena de la polimerasa. Ginecol Obstet Mex 2006; 74: 317-26.

12. Manci N, Marchetti C, Esposito F, Graziano M, Tomao F, Pastore M, et al. Late breast cancer recurrence to the uterine cervix with a review of the literature. Int J Gynecol Pathol 2008; 27: 113-7.

13. Lazcano-Ponce E. Factores de riesgo reproductivo asociados a cáncer cervical en México. Rev Invest Clin 1995; 47: 377-85.

14. González-Merlo J, Lejárcegui JA. Ginecología. 2a Ed. Editorial Masson-Salvat Medicina; 1994.

15. Rojas MR. Factores de riesgo reproductivo y cáncer cérvico-uterino en la ciudad de México. Rev Sal Pub Mex 1993; 35: 6-9.

16. Hans N, Cave AJ, Azafran O, Johnson G, Glass A, Spooner GR, et al. Papanicolaou smears: to swab or not to swab. Can Fam Physician 2007; 53: 1328-9.